Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents

Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma

Maintenance therapy with CC-486 for acute myeloid leukaemia

Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL

Multiple myeloma highlights from ASH 2019

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML

Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results